text,label,importance,correlations
"Press Release: ESMO: AlphaMedixTM phase 2 data support first-in-class potential of new targeted alpha therapy in gastroenteropancreatic neuroendocrine tumors. ESMO: AlphaMedix TM phase 2 data support first-in-class potential of new targeted alpha therapy in gastroenteropancreatic neuroendocrine tumors New AlphaMedix data showed sustained and clinically meaningful responses across both RLT-naïve and RLT-exposed patients with unresectable or metastatic GEP-NETs First phase 2 study to evaluate TAT with lead-212 supporting its potential to address high unmet medical needs in difficult-to-treat, rare cancers Phase 2 study met all primary efficacy endpoints and was presented across two oral presentations at the 2025 ESMO Congress in Berlin, Germany Paris, October 20, 2025. New data from the ALPHAMEDIX-02 phase 2 study (clinical study identifier: NCT05153772) evaluating AlphaMedix (212Pb-DOTAMTATE), an investigational somatostatin receptor (SSTR) targeted alpha therapy (TAT) using the lead-212 isotope, underscore the first-in-class potential of this investigational medicine for the treatment of patients with advanced gastroenteropancreatic neuroendocrine tumors (GEP-NETs).",positive,importante,CA:WHEAT;LU:FINANCIAL_SERVICES;FR:AIRCRAFT
"IO Biotech Presents Phase 3 Results for Cylembio® plus KEYTRUDA® (pembrolizumab) in First-line Advanced Melanoma at ESMO 2025. Cylembio plus pembrolizumab achieved a clinically relevant 19.4 months median progression free survival (mPFS) compared to 11.0 months mPFS with pembrolizumab alone; study narrowly missed progression free survival (PFS) primary endpoint for statistical significance Improvement in PFS favored the combination across virtually all subgroups, notably in patients with PD-L1-negative tumors, BRAF V600 -mutated tumors, and elevated LDH, without adding any systemic toxicity compared to pembrolizumab alone Final data from the Phase 2 basket trial in lung and head & neck cancers also presented NEW YORK, Oct. 20, 2025 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulatory, off-the-shelf therapeutic cancer vaccines, today presented detailed results from its global Phase 3 trial (IOB-013/KN-D18) of Cylembio® (imsapepimut and etimupepimut, adjuvanted), in combination with Merck's (known as MSD outside the United States and Canada) anti-PD-1 therapy KEYTRUDA® (pembrolizumab), for the first-line treatment of patients with unresectable or metastatic (advanced) melanoma. The data, presented as a proffered paper at the Melanoma and other skin tumors session of the 2025 European Society for Medical Oncology (ESMO) Congress in Berlin, expand upon topline results reported in August 2025.",positive,importante,CA:WHEAT;LU:FINANCIAL_SERVICES
"PUBM Investors Have Opportunity to Lead PubMatic, Inc. Securities Fraud Lawsuit with the Schall Law Firm. LOS ANGELES , Oct. 20, 2025 /PRNewswire/ -- The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against PubMatic, Inc. (""PubMatic"" or ""the Company"") (NASDAQ: PUBM) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between February 27, 2025 and August 11, 2025, inclusive (the ""Class Period""), are encouraged to contact the firm before October 20, 2025.",negative,importante,CA:WHEAT;LU:FINANCIAL_SERVICES;FR:AIRCRAFT
"NUTX Investors Have Opportunity to Lead Nutex Health Inc. Securities Fraud Lawsuit with the Schall Law Firm. LOS ANGELES , Oct. 20, 2025 /PRNewswire/ -- The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Nutex Health Inc. (""Nutex"" or ""the Company"") (NASDAQ: NUTX) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between August 8, 2024 and August 14, 2025, inclusive (the ""Class Period""), are encouraged to contact the firm before October 21, 2025.",negative,importante,CA:WHEAT;LU:FINANCIAL_SERVICES;AU:WHEAT
"Transgene and BioInvent's Armed Oncolytic Virus BT-001 Shows Positive Local, Abscopal, and Sustained Antitumoral Activity in Advanced Refractory Tumors. BT-001 in combination with pembrolizumab is well tolerated and shows sustained antitumoral activity in both injected and non-injected lesions Data support further development of BT-001 in solid tumors to improve response to cancer immunotherapy Strasbourg, France, and Lund, Sweden, October 20, 2025, 08:30 a.m. CEST – Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, and BioInvent International AB (“BioInvent”) (Nasdaq Stockholm: BINV), a biotech company focused on the discovery and development of novel and first-in-class antibodies for cancer immunotherapy, jointly presented a poster at the 2025 European Society for Medical Oncology (ESMO) Annual Meeting on updated clinical results and positive antitumoral activity of BT-001 in patients with advanced refractory tumors.",positive,générale,CA:WHEAT;LU:FINANCIAL_SERVICES
"Tocvan Advances Drilling, Trenching, and Pilot Mine Preparation, Mobilizing Equipment to North and South Blocks at Gran Pilar Gold-Silver Project. CALGARY, AB / ACCESS Newswire / October 20, 2025 / Tocvan Ventures Corp. (""Tocvan"" or the ""Company"") (CSE:TOC)(OTCQB:TCVNF)(WKN:TV3/A2PE64), is pleased to announce the mobilization of equipment to both the North and South Blocks of its flagship Gran Pilar Gold-Silver Project in Sonora, Mexico. This marks a significant step forward in preparing the site for upcoming drilling, trenching activities, and ground preparation for the planned pilot mine operation.",positive,générale,DE:AIRCRAFT;FR:ELECTRICITY
"NX Investors Have Opportunity to Lead Quanex Building Products Corporation Securities Fraud Lawsuit with the Schall Law Firm. LOS ANGELES , Oct. 20, 2025 /PRNewswire/ -- The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Quanex Building Products Corporation (""Quanex"" or ""the Company"") (NYSE: NX) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between December 12, 2024 and September 5, 2025, inclusive (the ""Class Period""), are encouraged to contact the firm before November 18, 2025.",negative,importante,DE:AIRCRAFT;FR:ELECTRICITY
"MLTX Investors Have Opportunity to Lead MoonLake Immunotherapeutics Securities Fraud Lawsuit with the Schall Law Firm. LOS ANGELES , Oct. 20, 2025 /PRNewswire/ -- The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against MoonLake Immunotherapeutics (""MoonLake"" or ""the Company"") (NASDAQ: MLTX) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between March 10, 2024 and September 29, 2025, inclusive (the ""Class Period""), are encouraged to contact the firm before December 15, 2025.",negative,importante,FR:BEVERAGES;FR:FINANCIAL_SERVICES
"TROX Investors Have Opportunity to Lead Tronox Holdings plc Securities Fraud Lawsuit with the Schall Law Firm. LOS ANGELES , Oct. 20, 2025 /PRNewswire/ --  The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Tronox Holdings plc (""Tronox"" or ""the Company"") (NYSE: TROX) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between February 12, 2025 and July 30, 2025, inclusive (the ""Class Period""), are encouraged to contact the firm before November 3, 2025.",negative,importante,CA:WHEAT;LU:FINANCIAL_SERVICES
"FLYE Investors Have Opportunity to Lead Fly-E Group, Inc. Securities Fraud Lawsuit with the Schall Law Firm. LOS ANGELES , Oct. 20, 2025 /PRNewswire/ -- The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Fly-E Group, Inc. (""Fly-E"" or ""the Company"") (NASDAQ: FLYE) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between July 15, 2025, and August 14, 2025, inclusive (the ""Class Period""), are encouraged to contact the firm before November 7, 2025.",negative,importante,CA:WHEAT;LU:FINANCIAL_SERVICES
"Exelixis Announces Detailed Results from Phase 3 STELLAR-303 Pivotal Trial Evaluating Zanzalintinib in Combination with an Immune Checkpoint Inhibitor in Metastatic Colorectal Cancer Presented at ESMO 2025 and Published in The Lancet. ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced detailed results from STELLAR-303, a global phase 3 pivotal trial evaluating zanzalintinib in combination with atezolizumab (Tecentriq®) versus regorafenib in patients with previously treated non-microsatellite instability (MSI)-high metastatic colorectal cancer (CRC). As previously announced, the study met one of its dual primary endpoints, demonstrating a 20% reduction in the risk of death with the combination in.",positive,importante,CA:WHEAT;LU:FINANCIAL_SERVICES
"Atlantic Lithium unearths significant potential at Rubino and Agboville projects. Atlantic Lithium Ltd (AIM:ALL, OTCQX:ALLIF, ASX:A11) has reported significant lithium-in-soil anomalies from Phase 2 and Phase 3 soil sampling across its 100%-owned Rubino and Agboville exploration licences in Côte d'Ivoire. The Africa-focused explorer said the results confirm extensive lithium trends, while additional spodumene pegmatite occurrences have been identified through geological mapping.",positive,importante,CA:WHEAT;LU:FINANCIAL_SERVICES;AU:WHEAT
"GENENTECH'S TECENTRIQ SHOWED SIGNIFICANT OVERALL AND DISEASE-FREE SURVIVAL BENEFITS IN BLADDER CANCER WITH CTDNA-GUIDED TREATMENT. SOUTH SAN FRANCISCO, CALIF.--(BUSINESS WIRE)--GENENTECH, A MEMBER OF THE ROCHE GROUP (SIX: RO, ROG; OTCQX: RHHBY), ANNOUNCED TODAY POSITIVE RESULTS FROM THE PHASE III IMVIGOR011 STUDY EVALUATING TECENTRIQ® (ATEZOLIZUMAB) AS AN ADJUVANT TREATMENT FOR PEOPLE WITH MUSCLE-INVASIVE BLADDER CANCER (MIBC) WHO ARE AT RISK OF RECURRENCE AFTER SURGERY (CYSTECTOMY) AND HAVE DETECTABLE CIRCULATING TUMOR DNA (CTDNA). IN THIS CTDNA-GUIDED SETTING, TECENTRIQ REDUCED THE RISK OF DEATH (OVERALL SURVIVAL, OS) BY.",positive,importante,
"Lazard Appoints Edouard Panié as Managing Director and Co-Head of European Financial Sponsors Coverage. LONDON & PARIS--(BUSINESS WIRE)--Lazard, Inc. (NYSE: LAZ) today announced the appointment of Edouard Panié as Managing Director and Co-Head of the European Financial Sponsors Coverage. He will report to Klaus H. Hessberger, Global Co-Head and Head of Europe for Lazard's Financial Sponsors Group, to further strengthen the firm's presence and partnerships with financial sponsors across the region. Mr. Panié joins from Goldman Sachs, where he was a Managing Director for nearly two decades, advisin.",positive,générale,
"VAALCO Schedules Third Quarter 2025 Earnings Release and Conference Call. HOUSTON, Oct. 20, 2025 (GLOBE NEWSWIRE) -- VAALCO Energy, Inc. (NYSE: EGY; LSE: EGY) (“Vaalco” or the “Company”) today announced the timing of its third quarter 2025 earnings release and conference call.",neutral,générale,FR:BEVERAGES;FR:FINANCIAL_SERVICES
"Kering to Sell Creed, License Fragrance Brands to L'Oreal in $4.7 Billion Deal. The deal marks an early move by Kering's new chief, Luca de Meo, to revive the French luxury giant's fortunes.",positive,importante,US:PETROLEUM_CRUDE;HK:SILVER
"Crypto prices today (Oct. 20): BTC, ETH, XRP rebound amid signs of easing U.S.-China trade tensions. Crypto prices today are stabilizing after a volatile weekend marked by a significant decline and shifting macro sentiment. The global cryptocurrency market added 3% in the past 24 hours to reach $3.",negative,générale,IN:IT_SERVICES
"HD Hyundai Vice Chairman Chung Kisun Promoted to Chairman. SEOUL, South Korea , Oct. 20, 2025 /PRNewswire/ -- HD Hyundai announced that Executive Vice Chairman Chung Kisun has been promoted to Chairman in its latest executive appointments. Chairman Chung holds a bachelor's degree in Economics from Yonsei University and an MBA from Stanford University in the United States.",neutral,générale,US:PETROLEUM_CRUDE;HK:SILVER
"Ripple CTO Weighs In on Jack Dorsey's 'Bitcoin Is Not Crypto' Remark. David Schwartz, chief technology officer at Ripple, has weighed in on the debate about Bitcoin not being part of crypto that was reignited by former Twitter CEO Jack Dorsey.",negative,générale,
"SUCCESSFUL IMVIGOR011 TRIAL ACHIEVES 41% IMPROVEMENT IN OVERALL SURVIVAL FOR BLADDER CANCER PATIENTS. AUSTIN, TEXAS--(BUSINESS WIRE)--NATERA, INC. (NASDAQ: NTRA), A GLOBAL LEADER IN CELL-FREE DNA AND PRECISION MEDICINE, TODAY ANNOUNCED RESULTS FROM THE RANDOMIZED, DOUBLE-BLIND, PHASE 3 IMVIGOR011 CLINICAL TRIAL IN MUSCLE-INVASIVE BLADDER CANCER (MIBC). THE FINDINGS DEMONSTRATE THAT SIGNATERA CAN EXPAND THE ADJUVANT TREATMENT WINDOW AND GUIDE THE USE OF ADJUVANT ATEZOLIZUMAB (TECENTRIQ®) IN MIBC, RESULTING IN IMPROVED DISEASE-FREE SURVIVAL (DFS) AND OVERALL SURVIVAL (OS). RESULTS WILL BE PRESENT.",positive,générale,
Pound Sterling Price News and Forecast: GBP/USD struggles to gain any meaningful traction amid mixed backdrop. Pound Sterling Price News and Forecast: GBP/USD struggles to gain any meaningful traction amid mixed backdrop,neutral,générale,
"ZachXBT Exposes $3 Million XRP Heist After Hardware Wallet Breach. On-chain sleuth ZachXBT has traced a $3.05 million theft of XRP from a US retail user to a laundering route that ran through Bridgers—an aggregator formerly associated with SWFT—and into over-the-counter venues linked to Huione, the Cambodian financial network that the US government moved last week to cut off from the American financial system.",negative,critique,
"Genflow Biosciences PLC Announces Recognition of Patentability of Claims. THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE MARKET ABUSE REGULATION (EU) NO. 596/2014 AS IT FORMS PART OF UK DOMESTIC LAW PURSUANT TO THE EUROPEAN UNION (WITHDRAWAL) ACT 2018, AS AMENDED.",neutral,importante,
"Tesco Share Price: As High As It Gets For Now. Despite popping on the day of the release of its interim results, the Tesco share price (LON:TSCO) looks to have peaked. With the shares struggling to breach their 450p price ceiling, I reiterate my previous call that further upside for the stock is limited at this juncture.",negative,importante,CA:WHEAT;LU:FINANCIAL_SERVICES
Bitcoin's next rally will start once OGs finish selling: Analysts. Long-term Bitcoin holders took profits at record levels with realized gains hitting $1.7 billion daily as older coins re-entered circulation.,neutral,importante,IN:IT_SERVICES
"Ethereum Price Could Rally Beyond $5,000 Soon, But There's a Catch. Ethereum retests key support as traders debate a $5K rally, with mixed technical and sentiment signals.",neutral,générale,
